LAUSR

To the editor Sudden cardiasc death (SCD) is a relevant complication after myocardial infarction (MI) and in patients suffering from heart failure with reduced ejection fraction. Current guidelines recommend an implantable cardioverter‐defibrillator (ICD) implantation earliest 40 days after MI and 90 days after revascularization in patients with left ventricular ejection fraction (LVEF) < 35% on optimal guideline‐ directed medical therapy. The wearable cardioverter defibrillator (WCD) may be considered as a bridging to protect patients against SCD until decision for permanent ICD implantation. In our recently published data, we investigated clinical outcome and adherence in a smaller cohort. To analyze gender differences, we investigated in a multicenter−multinational setting (nine centers) a large patient cohort treated with WCD (n = 1596) Table 1. Data from a total of 1596 patients (332 females, 20.8% and 1264 males, 79.2%) regarding indication for wearing WCD, WCD shocks, adherence, and clinical outcome after termination of WCD use at mean follow‐up of 20.6 ± 20.3 months were analyzed. Both